NEW METHOD FOR QSAR FOR BIOPHARMACEUTICAL PRODUCTS

这一创新旨在提供一种新的量化方法 生物药物构效关系(QSAR)分析 探员们。定量结构-活性关系的分析是 对合理的药物设计至关重要。而QSAR分析 被广泛用于常见的DUG，但对于各种类型的DUG几乎不存在 生物活性治疗剂的技术原因。阿纳利扎是 建议开发和验证一种新的量化方法 用于定量构效关系的疏水性质的测量 生物医药，如多肽、蛋白质、寡核苷酸等。 拟议的方法是独一无二的(就信息类型而言 获得的)、定量的和普遍的(因为可用于 完全不同化学性质的化合物的比较 结构)、廉价且易于执行(因此具有可行性和成本 当前结构优化技术的有效替代方案)。 此SBIR计划的第一阶段旨在验证 他建议的方法的可行性通过直接演示 一系列结构不同的多肽的QSAR分析 和具有不同生物活性的蛋白质 生物制药合作伙伴。 建议的商业应用： 定量结构-活性应用的新方法论 与生物治疗药物的关系(QSAR)分析将 提高化学改性的合理设计，有利于 制造效率更高的生物治疗剂， 安全性和稳定性。因此，它应该提供一个新的强大的工具来 在快速增长的生物制药领域取得的及时进展。

This innovation is aimed at providing a new methodology for quantitative structure-activity relationships (QSAR) analysis of biopharmaceutical agents. Analysis of quantitative structure-activity relationships is fundamentally important for rational drug design. While QSAR analysis is widely used for common dugs, it is virtually non-existent for various technical reason for biologically active therapeutic agents. ANALIZA is proposing to develop and validate a new methodology for quantitatie measurements of hydrophobic properties useful for QSAR of biopharmaceuticals, such as peptides, proteins, oligonucleotides, etc. The proposed methodology is unique ( in regard to the type of information obtained), quantitative and universal ( in that may be used for comparison of compounds of completely different chemical nature and structure), inexpensive and easy to perform (and thus a viable and cost effective alternative to current structure optimization techniques). Phase I portion of this SBIR program is designed to validate the feasibility of he proposed methodology via a direct demonstration of a QSAR analysis as applied to a series of structurally different peptides and proteins with varied biological activities as provided by biopharmaceutical partners. PROPOSED COMMERCIAL APPLICATION: A new methodology for application of quantitative structure-activity relationship (QSAR) analysis to biological therapeutic agents would improve rational design of chemical modifications beneficial for manufacturing of biological therapeutic agents with improved efficacy, safety, and stability. It should thus provide a new powerful tool for timely advancements in the rapidly growing field of biopharmaceuticals.